Auteur/autrice : Edouard Hueber

[Alerte actualité] Anticorps XAV-19

30 avril 2020 Download the press release / Télécharger le communiqué

[Infographie] Traitement XAV-19

Available here/Disponible ici

[Newsletter -1] NEWS / INFOS

May 1st, 2020. >> Official news bulletin for XAV-19/Bulletin officiel du XAV-19 << Download our newsletter (english version) Télécharger notre newsletter (version française)

In the news / A la une

Journal des Entreprises – Coronavirus – Xenothera : « Nous prenons des risques entrepreneuriaux en avançant sans les financements » le 23/04/20 – Caroline Scribe – Le monde de la recherche se bouge pour la lutte contre le Covid-19 (podcast inclus dans l’article) le 20/04/20 – Raphaëlle Duchemin Franchement Bien – Covid-19 : A Nantes, une biotech développe le Xav-19, un…
Lire la suite

COVID19 / XAV-19 : Scientific and medical rationale

Français ci-dessous «  We are convinced that our treatment will be efficient, for medical and scientific reasons today published in international scientific journals, namely by Chinese teams who have worked hard for 4 months, and with whom we have established our first contacts” says Odile Duvaux, MD and CEO of Xenothera Our arguments are the following:…
Lire la suite

Xenothera announces receivability of its Clinical Trial Application at the Czech Republic regulatory agency for a first in man clinical trial of LIS1 in kidney transplanted patients with dose escalation.

Nantes, June 21st, 2019 – Xenothera announces receivability after its submission of a Clinical Trial Application (CTA) with Czech Republic regulatory agency for a Phase I/II trial of its LIS1 product developed as induction treatment in solid organ transplantation. Upon CTA clearance, Xenothera plans to initiate a mono centric trial with volunteering kidney transplant patients. The clinical trial is…
Lire la suite